Stellate Ganglion Block and Prognosis of Neurological Function After Subarachnoid Hemorrhage
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Intervention group.
- Who it may be relevant to
- Registry conditions: Aneurysmal Subarachnoid Hemorrhage, Stellate Ganglion Block, Neurological Prognosis. Basic parameters: 18 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Effect of Stellate Ganglion Block on the Prognosis of Neurological Function After Subarachnoid Hemorrhage
Overview
The incidence of cerebral vasospasm after aneurysm subarachnoid hemorrhage (aSAH) is as high as 70%; cerebral vasospasm（CVS） is closely related to delayed cerebral ischemia （DCI）, which is one of the important reasons for poor outcomes in patients with aSAH. In recent years, it has been reported that stellate ganglion block(SGB) can effectively alleviate cerebral vasospasm(CVS), reduce cerebral blood flow velocity and increase cerebral perfusion in patients with aneurysm subarachnoid hemorrhage(aSAH)。However, whether the alleviation of CVS after SGB is beneficial to the long-term neurological prognosis has not been confirmed Therefore, a prospective randomized controlled study is needed to further explore the role of SGB block in improving the outcomes of patients with aSAH.
Interventions
- Procedure Intervention group
Prior to the initiation of surgery, a single ultrasound-guided stellate ganglion block was performed on the ipsilateral side of the lesion.The dose and concentration of local anesthesia: 0.5% ropivacaine 5-10ml. Criteria for successful block: the patient developed Horner's syndrome, characterized by miosis, ptosis, eyeball caved in, nasal congestion, conjunctival congestion, reddish face and no sweat on the face
Primary outcome measures
- The modified Rankin Scale (mRS) scores at 90 days [Time frame: 90 days postoperatively]
Secondary outcome measures (4)
- The incidence of delayed cerebral ischemia (DCI) during hospitalization [Time frame: At discharge, an average of 2 weeks]
- All cause mortality during 90 days after onset [Time frame: 90 days postoperatively]
- Length of stay in the intensive care unit and hosipital [Time frame: At discharge, an average of two weeks]
- Adverse events during hospitalization [Time frame: At discharge, an average of 2 weeks]
Eligibility criteria
Inclusion criteria
- Age range: 18-65 years old;
- Within 72 hours after onset of aSAH,and planning surgical treatment(aneurysm embolizing or clipping);
- Preoperative Hunt-Hess grade 2-3
- Sign informed consent.
Exclusion criteria
- ASA > grade IV;
- Patients with posterior circulation aneurysm;
- Patients with severe systemic hemorrhagic diseases;
- Patients with trauma and local infection in the nerve block area;
- Local anatomic structure changes (neck structure changes caused by radiotherapy, chemotherapy and surgery);
- Allergy to known local anesthetics;
- Pregnant and lactating women.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Prevention
Study locations
China · 1 center
- Beijing Tiantan Hospital, Capital Medical University — Beijing
Identifiers
NCT: NCT07652749 · Z191100006619069